Heudes D, Carli P M, Bailly F, Milan C, Mugneret F, Petrella T
Laboratoire d'Hématologie, Hôpital du Bocage, Dijon, France.
Nouv Rev Fr Hematol (1978). 1989;31(5):375-8.
By the registry of hematopoietic malignancies in Côte d'Or we studied the 177 cases of myeloproliferative disorders diagnosed between 1980 and 1986, divided into 4 groups: chronic myelogenous leukemia, idiopathic myelofibrosis, polycythemia vera, essential thrombocythemia. The global standardized rates based on the world population were 3.5 per 100,000 in men and 1.9 in women (sex ratio = 1.8). The mean age for myeloproliferative disorders was 61 +/- 16 years. Incidence was slightly higher in urban than in rural areas (NS). The most common means of detection were routine hemogram, fatigue and thrombosis. Five-year survival curves showed large differences in prognosis, from 30% for chronic myelogenous leukaemia to 83% for polycythaemia vera.
通过科多尔省造血系统恶性肿瘤登记处,我们研究了1980年至1986年间诊断出的177例骨髓增殖性疾病病例,分为4组:慢性粒细胞白血病、原发性骨髓纤维化、真性红细胞增多症、原发性血小板增多症。基于世界人口的全球标准化发病率男性为每10万人3.5例,女性为每10万人1.9例(性别比=1.8)。骨髓增殖性疾病的平均年龄为61±16岁。城市地区的发病率略高于农村地区(无统计学意义)。最常见的检测手段是常规血常规检查、疲劳和血栓形成。五年生存曲线显示预后差异很大,慢性粒细胞白血病为30%,真性红细胞增多症为83%。